Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer

British Journal of Cancer

Volumn 90, Issue 1, 2004, Pages 100-105

  Albrecht, W ^a   Van Poppel, H ^b   Horenblas, S ^c   Mickisch, G ^d   Horwich, A ^e   Serretta, V ^f   Casetta, G ^e   Marechal J M ^e   Jones, W G ^g   Kalman, S ^h   Sylvester, R ^h  

^a Rudolfstiftung   (Austria)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Antonie van Leeuwen Hoek Ziekenhuis   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Royal Marsden ^*  (France)

^f UNIVERSITY OF PALERMO   (Italy)

^g Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^h EORTC DATA CENTER   (Belgium)

Author keywords

EMP VBL vs EMP; Hormone escaped prostate cancer; Phase II

Indexed keywords

ESTRAMUSTINE PHOSPHATE; VINBLASTINE;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; ILLNESS BEHAVIOR; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NAUSEA; NEUROTOXICITY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT WITHDRAWAL; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 10744221004     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601468     Document Type: Article

References (23)

1. Amato RJ, Ellerhorst J, Bui C, Logothetis CJ (1995) Estramustine and vinblastine for patients with progressive androgen-independent adeno-carcinoma of the prostate. Urol Oncol 1: 168-172
2. Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E (1999) A pharmacokinetically guided phase II study of carboxyamido-triazole (CAI) in androgen independent prostate cancer. Clin Cancer Res 5: 2324-2329
3. Benson RC, Hartley-Asp B (1990) Mechanisms of action and clinical uses of estramustine. Cancer Invest 8: 375-380
4. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer, recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467
5. Crawford ED, Eisenberger MA, McLeod MA, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic cancer. New Engl J Med 321: 419-924
6. Dawson NA, McLeod DG (1997) The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Eur J Cancer 33: 560-565
7. Dexeus F, Logothetis CJ, Samuels ML, Hossan E, von Eschenbach AC (1995) Continous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 96: 885-886
8. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher H, Litwin S, Watts P, Speicher L, Tew K, Comis R (1992) Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761
9. Hudes GR, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B (1999) Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17: 3160-3166
10. Jones WG, Fossa SD, Bono AV, Croles JJ, Stoter G, de Pauw M, Sylvester R (1986) Mitomycin C in the treatment of metastatic prostate cancer: report on an EORTC phase II study (30804). World J Urol 4: 182-185
11. Kelly WK, Sher HI, Mazumadar M, Vlamis V, Schwartz M, Fossa SD (1993) Prostate specific antigen as a measure of desease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615
12. Mareel MM, Storme GA, Dragonetti CH, De Bruyne GK, Hartley-Asp B, Segers JL, Rabaey ML (1988) Anti-invasive activity of estramustine on malignant MO4 cells and on DU145 human prostate carcinoma cells in vitro. Cancer Res 48: 1842-1849
13. Newling DWW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R (1993) Mytomicin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organisation for Research and Treatment of Cancer, Genito Urinary Group prospective randomized Phase III Study (30865). J Urol 150: 1840-1844
14. Perry CA, McTavish D (1995) Estramustin phosphate sodium: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7: 149-174
15. Petrylak DP, MacArthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA (1999) Phase I trial of docetaxel with estramustin in androgen-independent prostate cancer. J Clin Oncol 17: 958-967
16. Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N (1999) A phase II study of docetaxel (Taxotere), estramustin, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and Leukemia Group B Trial 9780. Semin Oncol 26: 39-44
17. Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L (1990) Trimetrexate in prostate cancer: preliminary observations on the use of PSA and acid phosphatase as a marker in mesurable hormone-refractory disease. J Clin Oncol 8: 1830-1838
18. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T (1992) Estramustine phosphate and vinblastine: use of PSA as a clinical trial endpoint for hormone refractory prostate cancer. J Urol 147: 931-934
19. Sinibaldi VJ, Carducci M, Laufer M, Eisenberger M (1999) Preliminary evaluation of a short course of estramustin phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin Oncol 26: 45-48
20. Smith DC, Dunn RL, Strawderman MS, Pienta KJ (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835-1843
21. Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13: 2944-2953
22. Van Poppel H, Baert L (1991) The present role of estramustine phosphate in advanced prostate cancer. Progr Clin Biol Res 370: 323-341, (EORTC GU Group monograph 10)
23. Verbel DA, Heller G, Kelly WK, Scher HI (2002) Quantifying the amount of variation in survival explained by prostate-specific antigen. Clin Cancer Res 8: 2576-2579